vs
Amneal Pharmaceuticals, Inc.（AMRX）与Element Solutions Inc（ESI）财务数据对比。点击上方公司名可切换其他公司
Element Solutions Inc的季度营收约是Amneal Pharmaceuticals, Inc.的1.0倍（$840.0M vs $814.3M），Element Solutions Inc净利率更高（6.7% vs 4.3%，领先2.4%），Element Solutions Inc同比增速更快（41.0% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $-74.2M），过去两年Element Solutions Inc的营收复合增速更高（17.1% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Element Solutions Inc是一家总部位于美国的特种化学品生产企业，专注于特种化学品领域的生产运营，于纽约证券交易所挂牌上市，业务覆盖全球多个市场，为各行业客户提供专业的特种化学品产品及相关解决方案。
AMRX vs ESI — 直观对比
营收规模更大
ESI
是对方的1.0倍
$814.3M
营收增速更快
ESI
高出29.5%
11.5%
净利率更高
ESI
高出2.4%
4.3%
自由现金流更多
AMRX
多$182.7M
$-74.2M
两年增速更快
ESI
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $840.0M |
| 净利润 | $35.1M | $56.0M |
| 毛利率 | 36.5% | 38.4% |
| 营业利润率 | 13.8% | 13.3% |
| 净利率 | 4.3% | 6.7% |
| 营收同比 | 11.5% | 41.0% |
| 净利润同比 | 212.9% | -42.9% |
| 每股收益（稀释后） | $0.10 | $0.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXESI
| Q1 26 | — | $840.0M | ||
| Q4 25 | $814.3M | $676.2M | ||
| Q3 25 | $784.5M | $656.1M | ||
| Q2 25 | $724.5M | $625.2M | ||
| Q1 25 | $695.4M | $593.7M | ||
| Q4 24 | $730.5M | $624.2M | ||
| Q3 24 | $702.5M | $645.0M | ||
| Q2 24 | $701.8M | $612.7M |
净利润AMRXESI
| Q1 26 | — | $56.0M | ||
| Q4 25 | $35.1M | $6.2M | ||
| Q3 25 | $2.4M | $39.3M | ||
| Q2 25 | $22.4M | $47.4M | ||
| Q1 25 | $12.2M | $98.0M | ||
| Q4 24 | $-31.1M | $54.7M | ||
| Q3 24 | $-156.0K | $40.3M | ||
| Q2 24 | $6.0M | $93.2M |
毛利率AMRXESI
| Q1 26 | — | 38.4% | ||
| Q4 25 | 36.5% | 40.9% | ||
| Q3 25 | 34.9% | 42.2% | ||
| Q2 25 | 39.5% | 42.6% | ||
| Q1 25 | 36.8% | 42.2% | ||
| Q4 24 | 36.0% | 41.0% | ||
| Q3 24 | 38.4% | 41.5% | ||
| Q2 24 | 35.6% | 43.6% |
营业利润率AMRXESI
| Q1 26 | — | 13.3% | ||
| Q4 25 | 13.8% | 10.3% | ||
| Q3 25 | 9.0% | 15.4% | ||
| Q2 25 | 15.4% | 15.1% | ||
| Q1 25 | 14.4% | 13.0% | ||
| Q4 24 | 10.4% | 12.0% | ||
| Q3 24 | 12.6% | 14.7% | ||
| Q2 24 | 13.6% | 15.7% |
净利率AMRXESI
| Q1 26 | — | 6.7% | ||
| Q4 25 | 4.3% | 0.9% | ||
| Q3 25 | 0.3% | 6.0% | ||
| Q2 25 | 3.1% | 7.6% | ||
| Q1 25 | 1.8% | 16.5% | ||
| Q4 24 | -4.3% | 8.8% | ||
| Q3 24 | -0.0% | 6.2% | ||
| Q2 24 | 0.9% | 15.2% |
每股收益（稀释后）AMRXESI
| Q1 26 | — | $0.23 | ||
| Q4 25 | $0.10 | $0.03 | ||
| Q3 25 | $0.01 | $0.16 | ||
| Q2 25 | $0.07 | $0.20 | ||
| Q1 25 | $0.04 | $0.40 | ||
| Q4 24 | $-0.10 | $0.22 | ||
| Q3 24 | $0.00 | $0.17 | ||
| Q2 24 | $0.02 | $0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $177.3M |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $2.7B |
| 总资产 | $3.7B | $5.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXESI
| Q1 26 | — | $177.3M | ||
| Q4 25 | $282.0M | $626.5M | ||
| Q3 25 | $201.2M | $594.3M | ||
| Q2 25 | $71.5M | $529.9M | ||
| Q1 25 | $59.2M | $499.2M | ||
| Q4 24 | $110.6M | $359.4M | ||
| Q3 24 | $74.0M | $376.0M | ||
| Q2 24 | $43.8M | $309.3M |
总债务AMRXESI
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $1.6B | ||
| Q3 25 | $2.6B | $1.6B | ||
| Q2 25 | $2.2B | $1.6B | ||
| Q1 25 | $2.2B | $1.6B | ||
| Q4 24 | $2.4B | $1.8B | ||
| Q3 24 | $2.4B | $1.9B | ||
| Q2 24 | $2.4B | $1.9B |
股东权益AMRXESI
| Q1 26 | — | $2.7B | ||
| Q4 25 | $-70.8M | $2.7B | ||
| Q3 25 | $-109.5M | $2.7B | ||
| Q2 25 | $-112.1M | $2.6B | ||
| Q1 25 | $-131.7M | $2.5B | ||
| Q4 24 | $-109.3M | $2.4B | ||
| Q3 24 | $-93.4M | $2.4B | ||
| Q2 24 | $-57.5M | $2.4B |
总资产AMRXESI
| Q1 26 | — | $5.7B | ||
| Q4 25 | $3.7B | $5.1B | ||
| Q3 25 | $3.6B | $5.0B | ||
| Q2 25 | $3.4B | $5.0B | ||
| Q1 25 | $3.4B | $4.8B | ||
| Q4 24 | $3.5B | $4.9B | ||
| Q3 24 | $3.5B | $5.1B | ||
| Q2 24 | $3.5B | $5.0B |
负债/权益比AMRXESI
| Q1 26 | — | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | 0.64× | ||
| Q4 24 | — | 0.76× | ||
| Q3 24 | — | 0.78× | ||
| Q2 24 | — | 0.81× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | — |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $-74.2M |
| 自由现金流率自由现金流/营收 | 13.3% | -8.8% |
| 资本支出强度资本支出/营收 | 2.7% | 3.0% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | — |
8季度趋势，按日历期对齐
经营现金流AMRXESI
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | — | ||
| Q3 25 | $118.5M | $100.1M | ||
| Q2 25 | $83.8M | — | ||
| Q1 25 | $7.4M | $26.0M | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $141.8M | $98.5M | ||
| Q2 24 | $39.7M | — |
自由现金流AMRXESI
| Q1 26 | — | $-74.2M | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | $83.6M | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | $15.0M | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | $85.9M | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXESI
| Q1 26 | — | -8.8% | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | 12.7% | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | 2.5% | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | 13.3% | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXESI
| Q1 26 | — | 3.0% | ||
| Q4 25 | 2.7% | 2.5% | ||
| Q3 25 | 1.6% | 2.5% | ||
| Q2 25 | 3.2% | 2.8% | ||
| Q1 25 | 1.9% | 1.9% | ||
| Q4 24 | 2.1% | 3.6% | ||
| Q3 24 | 2.4% | 2.0% | ||
| Q2 24 | 1.5% | 2.4% |
现金转化率AMRXESI
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | 2.55× | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | 0.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.44× | ||
| Q2 24 | 6.62× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
ESI
| Electronics ex-Metals | $377.8M | 45% |
| Pass-through Metals | $255.7M | 30% |
| Other | $206.5M | 25% |
